Long viewed as simply annoying habits, sleep disordered breathing (SDB) problems like snoring are, in fact, often symptoms of more severe conditions, most commonly obstructive sleep apnea (OSA). New clinical evidence is confirming the theories of early sleep medicine physicians that, in addition to causing snoring, headaches and excessive daytime sleepiness, OSA leads to severe cerebro- and cardiovascular complications, including hypertension, stroke, heart attack and sudden cardiac death. Studies are also revealing that SDB problems are extremely widespread, afflicting an estimated 40 million Americans, yet only a small percentage of those are diagnosed and treated. Very few patients are ever cured because the traditional surgical procedures that can eliminate OSA are extremely traumatic and often don't work. ResMed is fighting a two-tiered battle in attempting to develop and market devices to effectively treat OSA: first is getting patients to acknowledge and physicians to diagnose and treat this condition, and second is designing a device that is sufficiently patient-friendly to overcome what has been the Achilles heel of OSA treatment: poor patient compliance.
by Stephen Levin
The question of what Boris Yeltsin, Helmut Kohl, US senators Max Cleland and Jay Rockefeller, and comedian Dom DeLuise have...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Jason Menzo, CEO of the Foundation Fighting Blindness, says the organization is adapting its funding strategy, navigating regulatory challenges and accelerating the translation of academic discoveries into industry-led clinical development.
Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.
While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”
While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
